Redcare Pharmacy raises again full-year 2026 revenue guidance driven by strong Rx momentum in Germany
Published on 09/28/2026 at 13:48 | dgap, AD HOC NEWS| EQS-Ad-hoc: Redcare Pharmacy N.V. / Key word(s): Forecast / Full year 28-Sep-2026 / 13:48 CET/CEST Disclosure of an inside information acc. to Article 17 MAR of the Regulation (EU) No 596/2014, transmitted by EQS News - a service of EQS Group. The issuer is solely responsible for the content of this announcement. Sevenum, the Netherlands, September 28, 2026. Redcare Pharmacy N.V. announces that it is raising its full-year 2026 guidance for the second time this year, driven by continued strong Rx revenue momentum in Germany. The Company now expects: Total revenue growth of 16% to 18% (previously: 15% to 17%) Non-Rx growth of 10% to 12% (unchanged) Rx revenue in Germany between EUR 730 and 760 million, representing growth of 45% to 51% (previously: EUR 680 to 720 million, representing growth of 35% to 43%) Adjusted EBITDA margin between 2.5% and 3.0% (unchanged) Contact: Irina Zhurba Investor Relations Redcare Pharmacy End of Inside Information 28-Sep-2026 CET/CEST The EQS Distribution Services include Regulatory Announcements, Financial/Corporate News and Press Releases. View original content: EQS News |
| Language: | English |
| Company: | Redcare Pharmacy N.V. |
| Erik de Rodeweg 11-13 | |
| 5975 WD Sevenum | |
| Netherlands | |
| Phone: | 0800 - 200 800 300 |
| Fax: | 0800 - 90 70 90 20 |
| E-mail: | investors@redcare-pharmacy.com |
| Internet: | www.redcare-pharmacy.com |
| ISIN: | NL0012044747, DE000A19Y072 |
| WKN: | A2AR94, A19Y072 |
| Indices: | SDAX |
| Listed: | Regulated Market in Frankfurt (Prime Standard); Regulated Unofficial Market in Dusseldorf, Hamburg, Hanover, Munich, Stuttgart, Tradegate BSX |
| LEI Code: | 529900JK6UXHY1YKZ082 |
| EQS News ID: | 2406332 |
| End of Announcement | EQS News Service |
| |
2406332 28-Sep-2026 CET/CEST
en | NL0012044747 | REDCARE PHARMACY N.V. | boerse | 70192656 |
